A prospective randomized trial of intravenous magnesium versus intravenous propranolol in acute myocardial infarction.
A total of 266 patients entered into a study comparing the effect of intravenous magnesium and propranolol following acute myocardial infarction. Of these, 97 were able to receive either drug and were therefore randomized into the magnesium (n = 51) or propranolol group (n = 46). 88 patients were unable to receive propranolol and formed a third group (NR) while a further 81 patients could not receive either drug and formed a fourth group (N). The study showed that intravenous magnesium was as effective in preventing potentially lethal arrhythmias as propranolol and could be given to some 70 per cent of such patients whereas propranolol could only be given to 36 per cent.
Balkin
J
J
Department of Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel.
Rosenmann
D
D
Ilan
M
M
Klutstein
M
M
Zion
M M
MM
Abraham
A S
AS
D000368:Aged; D005260:Female; D006327:Heart Block / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D015994:Incidence; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008278:Magnesium Sulfate / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D011433:Propranolol / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D011654:Pulmonary Edema / Q000453:epidemiology / Q000209:etiology; D012770:Shock, Cardiogenic / Q000453:epidemiology / Q000209:etiology; D016896:Treatment Outcome; D014693:Ventricular Fibrillation / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control
D008278:Magnesium Sulfate; D011433:Propranolol